Uniqure (NASDAQ:QURE) released its earnings results on Thursday. The biotechnology company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.31), MarketWatch Earnings reports. The firm had revenue of $1.54 million during the quarter, compared to analysts’ expectations of $17.87 million. Uniqure had a negative net margin of 2,553.30% and a negative return on equity of 42.00%.
NASDAQ:QURE opened at $41.73 on Friday. Uniqure has a 52 week low of $36.20 and a 52 week high of $76.69. The company has a quick ratio of 12.89, a current ratio of 12.89 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $1.85 billion, a P/E ratio of -13.29 and a beta of 1.24. The stock’s fifty day moving average is $49.97 and its two-hundred day moving average is $55.53.
Several research firms have recently weighed in on QURE. Mizuho restated a “hold” rating and issued a $61.00 target price on shares of Uniqure in a research report on Tuesday, July 14th. BidaskClub downgraded Uniqure from a “sell” rating to a “strong sell” rating in a research report on Friday. Robert W. Baird upgraded Uniqure from a “neutral” rating to an “outperform” rating and reduced their price objective for the stock from $58.00 to $57.00 in a research report on Friday. ValuEngine downgraded Uniqure from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 14th. Finally, Zacks Investment Research upgraded Uniqure from a “hold” rating to a “buy” rating and set a $52.00 price objective on the stock in a research report on Tuesday, June 30th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $73.92.
In other news, insider Robert Gut sold 26,875 shares of Uniqure stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $70.00, for a total value of $1,881,250.00. Also, CEO Matthew C. Kapusta sold 5,626 shares of Uniqure stock in a transaction on Wednesday, July 22nd. The shares were sold at an average price of $42.31, for a total value of $238,036.06. Following the completion of the sale, the chief executive officer now directly owns 298,525 shares of the company’s stock, valued at $12,630,592.75. The disclosure for this sale can be found here. Insiders sold 40,002 shares of company stock worth $2,614,652 in the last 90 days. Company insiders own 2.66% of the company’s stock.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Featured Story: What are the reasons investors use put options?
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.